CanAssist Breast is our flagship product which uses a proprietary Artificial Intelligence-based statistical model to identify the patient's risk of breast cancer recurrence over five years. It is a prognostic test that analyses the critical biomarkers in the tumour and classifies the patients into "low- risk" or "high-risk" for cancer recurrence. Based on the risk scores, the oncologists can frame an informed and personalized treatment plan wherein the low-risk patients can safely avoid chemotherapy.

Choose the right treatment with CanAssist Breast by weighing the risks and benefits of chemotherapy.